NCT04617002 2025-08-20
Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas
Jazz Pharmaceuticals
Approved for marketing
Clinical Trials
11 trialsNCT06743100 2025-04-02
18F-Floretyrosine Expanded Access Program
Telix Pharmaceuticals (Innovations) Pty Limited
Available
NCT05592743 2024-11-05
Vorasidenib Expanded Access Program
Servier
Approved for marketing
NCT04714086 2024-10-24
Expanded Access Program for Avapritinib
Blueprint Medicines Corporation
No longer available
NCT05760586 2024-08-12
Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma
Day One Biopharmaceuticals, Inc.
Approved for marketing
NCT05356312 2024-03-01
Glioblastoma and Individualized Therapies
Zentrum fur Humangenetik Tuebingen
Available
NCT05392374 2022-05-26
Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas
Jazz Pharmaceuticals
No longer available
NCT04289155 2022-03-17
Individual Patient Compassionate Use of GX-I7
Genexine, Inc.
No longer available
NCT03134131 2022-03-14
Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas
Jazz Pharmaceuticals
No longer available
NCT03460782 2019-11-08
An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas
Center Trials & Treatment
No longer available
NCT03311542 2018-01-10
Expanded Access for Pembrolizumab (MK-3475)
Center Trials & Treatment
No longer available